30.17
price down icon1.02%   -0.31
after-market After Hours: 29.58 -0.59 -1.96%
loading
Lenz Therapeutics Inc stock is traded at $30.17, with a volume of 273.09K. It is down -1.02% in the last 24 hours and down -7.25% over the past month. LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$30.48
Open:
$30.24
24h Volume:
273.09K
Relative Volume:
0.91
Market Cap:
$860.51M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-5.3901
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-1.92%
1M Performance:
-7.25%
6M Performance:
+13.04%
1Y Performance:
+28.11%
1-Day Range:
Value
$29.12
$30.71
1-Week Range:
Value
$27.79
$31.59
52-Week Range:
Value
$16.54
$38.93

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name
Name
Lenz Therapeutics Inc
Name
Phone
858-925-7000
Name
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Name
Employee
42
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
LENZ's Discussions on Twitter

Compare LENZ with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LENZ
Lenz Therapeutics Inc
30.17 869.35M 0 -69.47M -73.92M -5.5973
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
385.65 96.11B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.13 60.40B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
428.14 54.91B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.15 41.30B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
298.52 33.25B 3.81B -644.79M -669.77M -6.24

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-14-25 Resumed Piper Sandler Overweight
Mar-18-25 Initiated TD Cowen Buy
Sep-27-24 Initiated Raymond James Outperform
Aug-12-24 Initiated H.C. Wainwright Buy
Apr-15-24 Initiated Leerink Partners Outperform
Apr-15-24 Initiated William Blair Outperform
Apr-10-24 Initiated Citigroup Buy
Mar-27-24 Initiated Piper Sandler Overweight
Feb-23-23 Downgrade BofA Securities Neutral → Underperform
Feb-23-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-23-23 Downgrade Cowen Outperform → Market Perform
Jan-25-23 Downgrade BTIG Research Buy → Neutral
Jan-18-23 Downgrade BofA Securities Buy → Neutral
Jan-06-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-06-23 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-15-22 Initiated Cantor Fitzgerald Overweight
Jun-17-22 Initiated BMO Capital Markets Outperform
Apr-14-22 Initiated BTIG Research Buy
Mar-22-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-18-22 Initiated RBC Capital Mkts Sector Perform
Jul-20-21 Initiated Morgan Stanley Overweight
Jul-20-21 Initiated SVB Leerink Outperform
View All

Lenz Therapeutics Inc Stock (LENZ) Latest News

pulisher
Aug 05, 2025

A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks

Aug 05, 2025
pulisher
Aug 04, 2025

LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa

Aug 04, 2025
pulisher
Aug 04, 2025

LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Australia

Aug 04, 2025
pulisher
Aug 03, 2025

What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Using data models to predict LENZ Therapeutics Inc. stock movementTen-Year Sector Performance and Summary Analysis - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Published on: 2025-08-01 19:39:34 - Newser

Aug 02, 2025
pulisher
Aug 01, 2025

Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare

Aug 01, 2025
pulisher
Aug 01, 2025

FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare

Aug 01, 2025
pulisher
Aug 01, 2025

Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech

Aug 01, 2025
pulisher
Aug 01, 2025

LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl

Aug 01, 2025
pulisher
Aug 01, 2025

LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha

Aug 01, 2025
pulisher
Aug 01, 2025

LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com

Aug 01, 2025
pulisher
Aug 01, 2025

Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

Citigroup maintains Buy rating on LENZ Therapeutics, raises PT to $49. - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant

Jul 31, 2025
pulisher
Jul 31, 2025

Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia

Jul 31, 2025
pulisher
Jul 31, 2025

Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool

Jul 31, 2025
pulisher
Jul 31, 2025

Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World

Jul 31, 2025
pulisher
Jul 31, 2025

LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Biotech Stocks Under FDA Review in August 2025: LENZ Therapeutics and PharmaTher Holdings - AInvest

Jul 30, 2025
pulisher
Jul 30, 2025

LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Australia

Jul 30, 2025
pulisher
Jul 30, 2025

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times

Jul 30, 2025
pulisher
Jul 30, 2025

LENZ Therapeutics and the Imminent FDA Decision for LNZ100: A High-Conviction Biotech Play Ahead of PDUFA - AInvest

Jul 30, 2025

Lenz Therapeutics Inc Stock (LENZ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lenz Therapeutics Inc Stock (LENZ) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Versant Venture Capital VI, L.
10% Owner
Jun 27 '25
Sale
30.46
200,000
6,093,000
1,767,275
Versant Venture Capital VI, L.
10% Owner
Jun 20 '25
Sale
30.25
133,924
4,051,201
1,967,275
Versant Venture Capital VI, L.
10% Owner
Jun 20 '25
Sale
30.35
100,877
3,061,617
1,047,912
Versant Venture Capital VI, L.
10% Owner
Jun 18 '25
Sale
29.95
100,000
2,995,000
1,148,789
Versant Venture Capital VI, L.
10% Owner
Jun 10 '25
Sale
29.00
350,000
10,150,000
1,248,789
Olsson Shawn
Chief Commercial Officer
Apr 09 '25
Option Exercise
2.08
1,400
2,912
4,733
Schimmelpennink Evert B.
President, CEO and Secretary
Mar 07 '25
Option Exercise
1.04
4,200
4,368
49,200
Olsson Shawn
Chief Commercial Officer
Dec 16 '24
Option Exercise
2.08
3,333
6,933
3,333
$77.65
price down icon 0.10%
$37.12
price down icon 2.08%
$111.26
price down icon 0.31%
$28.52
price down icon 2.09%
$111.30
price up icon 0.21%
biotechnology ONC
$298.52
price down icon 2.84%
Cap:     |  Volume (24h):